UK markets close in 5 hours 9 minutes
  • FTSE 100

    7,174.99
    +52.67 (+0.74%)
     
  • FTSE 250

    22,718.91
    +72.83 (+0.32%)
     
  • AIM

    1,178.61
    -3.69 (-0.31%)
     
  • GBP/EUR

    1.1742
    +0.0052 (+0.44%)
     
  • GBP/USD

    1.3271
    +0.0036 (+0.27%)
     
  • BTC-GBP

    35,744.97
    -1,650.18 (-4.41%)
     
  • CMC Crypto 200

    1,209.58
    -232.18 (-16.10%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.72 (-0.17%)
     
  • CRUDE OIL

    68.05
    +1.79 (+2.70%)
     
  • GOLD FUTURES

    1,781.60
    -2.30 (-0.13%)
     
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • HANG SENG

    23,349.38
    -417.31 (-1.76%)
     
  • DAX

    15,189.23
    +19.25 (+0.13%)
     
  • CAC 40

    6,802.68
    +37.16 (+0.55%)
     

Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

·4-min read
Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting